Remus plans semaglutide launch soon after product approvals

Remus said in its Q2/H1-FY27 update that approved semaglutide tablets and injections are planned for commercialization soon, while consolidated operational revenue rose 53.4% year on year to Rs 614.1 crore in H1-FY27. The company did not identify the approving country or regulator.

What semaglutide products has Remus approved?

Remus reported approval for two semaglutide dosage formats: tablets and injections. The statement appeared in the company’s Q2/H1-FY27 operational highlights under the heading “Biological Products,” indicating that Remus presents these products as part of its biological-products portfolio rather than its anti-infective, anti-allergy or central nervous system, or CNS, patch activities.

The H1-FY27 presentation does not identify the country or regulator that granted the approvals, nor does it state the tablet strength, injection strength, brand name or launch volumes. The reported fact is therefore limited to approval of semaglutide tablets and injections, while the commercial scale and market-by-market availability remain undisclosed in the H1-FY27 update.

When will Remus commercialize approved semaglutide products?

Remus said commercialization of the approved semaglutide tablets and injections is planned soon, but did not provide a launch date. The wording separates the regulatory milestone reported in H1-FY27 from the next commercial step, so the presentation does not establish whether sales, shipments or customer orders for either semaglutide format had begun by the reporting period.

That distinction is visible elsewhere in the H1-FY27 update. Remus described supply orders for Rotigotine Patches in Venezuela as executed, while it described semaglutide commercialization as planned. Likewise, the company said it had received product trademarks and brand approvals in the Dominican Republic but was planning a business-to-consumer, or B2C, launch there soon, showing that product approval and launch activity can occur at separate stages.

How does semaglutide fit Remus's biological products pipeline?

Semaglutide expands the biological-products line disclosed by Remus alongside discussions to in-license several additional biosimilar products. Remus did not name those prospective biosimilars, counterparties, markets or expected timing in H1-FY27, so the discussions should not be treated as completed in-licensing transactions or as products already contributing revenue.

The portfolio update combines products at different stages and in several markets. Remus said it in-licensed several new molecules for Mexico, Chile, Vietnam and Peru, backed by bioequivalence, or BE, studies, to strengthen its anti-infective and anti-allergy portfolio. Separately, it plans to introduce more than five new own-label brands in Guatemala, while the semaglutide entry is reported as an approval followed by a planned commercialization step.

What other overseas product progress did Remus report in H1-FY27?

Remus reported winning a tender covering 24 products in Bolivia and securing a direct government tender in Venezuela during Q2/H1-FY27. The company also reported product registration and approval activity in Venezuela, although the presentation does not identify the products, tender values, contract duration or revenue expected from the Bolivia and Venezuela tender announcements.

In Peru, Remus said its plant had been approved by Digemid and that it was currently filling more than 60 products. In Venezuela, it executed supply orders for Rotigotine Patches and initiated filings in Venezuela and other markets. Remus described Rotigotine as its second patch launch in the market, linking the order execution to its stated expansion of the CNS portfolio.

The H1-FY27 update therefore shows distinct routes to market across countries: tenders in Bolivia and Venezuela, filling activity in Peru, in-licensed molecules for four Latin American and Asian markets, and own-label brands in Guatemala. Semaglutide is different from the reported Rotigotine orders because Remus disclosed an approval and intended commercialization, rather than completed supply orders, for the tablets and injections.

What financial performance accompanied Remus's H1-FY27 pipeline update?

Remus reported consolidated operational revenue of Rs 614.1 crore in H1-FY27, up from Rs 400.2 crore in H1-FY26, while consolidated profit after tax, or PAT, rose to Rs 24.7 crore from Rs 21.6 crore. The presentation does not attribute any part of this revenue or profit movement to semaglutide, the 24-product Bolivia tender, Rotigotine Patches or any prospective biosimilar in-licensing.

Revenue increased by Rs 213.9 crore year on year, while EBITDA rose by Rs 3 crore. Consequently, the reported consolidated EBITDA margin declined by 185 basis points to 4.87% in H1-FY27 from 6.72% in H1-FY26, and PAT margin declined by 138 basis points to 4.02% from 5.40%. These financial results provide period context for the operational update but do not measure the financial effect of products whose commercialization remains planned.

Conclusion

The H1-FY27 disclosure establishes that Remus reported approval for both semaglutide tablets and injections, adding the two formats to its disclosed biological-products portfolio alongside discussions on further biosimilar in-licensing. This sits within a broader overseas update that includes 24 products tendered in Bolivia, more than 60 products being filled in Peru and a second patch launch through Rotigotine supply orders in Venezuela.

The next reported milestone is commercialization of the approved semaglutide products, for which Remus gave no country, launch date, strength or sales target. The presentation also leaves unresolved whether discussions on several biosimilars will result in executed in-licensing agreements and whether planned B2C activity in the Dominican Republic and more than five own-label brands in Guatemala will move into reported sales.